ReviR Therapeutics

About ReviR Therapeutics

ReviR Therapeutics is a pioneering biotechnology company focused on improving human health through drug discovery using RNA and AI technologies. Their mission involves developing novel small molecule RNA modulators to treat neurogenetic diseases and other disorders like Huntington's Disease.

Products & Services

VoyageR Discovery Engine:A proprietary platform featuring an RNA-targeting compound library, transcriptome-wide compound screening, and AI-driven drug/target discovery for developing therapies.

Small Molecule RNA Modulators:Therapeutics targeting neurogenetic diseases such as Huntington's Disease, spinal and bulbar muscular atrophy (SBMA), and Charcot-Marie-Tooth disease (CMT1A), as well as oncology indications like genitourinary tumors.

Oral Genetic Medicines:Innovative oral therapies for multiple central nervous system (CNS) disorders.

Specialties

RNA-targeted technologies AI-driven drug discovery Small molecule RNA modulators Neurogenetic disease treatment Oncology therapeutics

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Series A T: - FT: Series A	A: 30000000 MR: - FA: 30 million FAN: 30000000	D: 2024-07-26 FD: 2024-07-26	6 investors

Series A Latest

2024-07-26

$30.0M

6 investors (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

P

Peng Yue

Co-founder, CEO

P

Paul August

CSO

S

Sarah Burnett

Head of Business Development

S

Sridhar Narayan

VP of Medicinal Chemistry

Y

Yang Liu

VP of Computing

J

Jinxing Li

Director of Medicinal Chemistry

View 5 more team members with Pro

Unlock Full Team Directory

Recent News